Rigorous efficacy studies are next.
To determine the feasibility, safety and efficacy of tight glycaemic control in patients on an AMU.
Therefore, the combination of an insufficient difference between the treatment groups in blood glucose values and lack of power makes it impossible to draw any conclusion on the efficacy of tight glycaemic control.
The aim of this phase II study was to determine the feasibility, safety and efficacy of tight glycaemic control with insulin in COPD patients with exacerbations on acute medical wards, towards testing this intervention in a randomised controlled trial.
It was an important update to earlier guidelines (2– 8), providing a thorough examination of the ever-more-complex therapeutic options for glycemic management, the benefits and risks of tight glycemic control, the efficacy and safety evidence for new drug classes, and the data supporting withdrawals of or restrictions on other agents.
In addition, in the BeSt study, treatment with infliximab and methotrexate combined with a tight control of treatment efficacy (DAS-based treatment adjustments every 3 months), resulted in a DAS remission in 56% of patients after 13 months of treatment; these patients continued with methotrexate monotherapy without the need to restart infliximab in the subsequent months.
In light of their tightest confidence intervals for efficacy, TNF-inhibitors (+ MTX) should be the comparator of choice [ 103].
Several large randomized controlled trials were stopped due to unacceptably high rates of severe hypoglycemia (blood glucose (BG) <2.2 mmol/L), 9.8% of patients in the Glucontrol study [ 9] and 17.0% of the tight control group in the Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis (VISEP) study [ 10].
Then, we assessed the efficacy of MR16-1 in tight skin-1 (Tsk-1) mice, an inflammation-independent model of skin fibrosis.
The efficacy and safety of tight glycaemic control were similar in COPD patients on acute medical wards to that achieved in intensive care settings, with improved glycaemic control but increased hypoglycaemia and glycaemic variability.
